Press Releases

Ligand to Present at Upcoming Investor Conferences

SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand, is scheduled to present at the following upcoming investor conferences:

  • 12th Annual Needham Healthcare Conference in New York, NY. Presentation: Tuesday, April 30, 2013 at 8:00 a.m. Eastern (5:00 a.m. Pacific).
  • Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas, NV. Presentation: Wednesday, May 15, 2013 at 2:20 p.m. Eastern (11:20 a.m. Pacific).

A live webcast of these presentations will be available on Ligand’s website at www.ligand.com. A replay of the presentations will be archived there for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly & Co., Spectrum Pharmaceuticals and The Medicines Company. Please visit www.captisol.com for more information on Captisol or www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Jennifer Capuzelo, Investor Relations
jcapuzelo@ligand.com
(858) 550-7584
or
LHA
Don Markley
dmarkley@lhai.com
(310) 691-7100

Source: Ligand Pharmaceuticals Incorporated